+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The Corporate Reputation of Pharma in 2019 - The Patient Perspective - Mental Health Edition: The Views of 75 Mental Health Patient Groups

  • ID: 5174359
  • Report
  • August 2020
  • Region: Global
  • PatientView
1 of 4
What 75 Mental-Health Patient Groups Think of 6 Pharma Companies in 2019

FEATURED COMPANIES

  • Eli Lilly
  • Janssen
  • Lundbeck
  • Otsuka
  • Pfizer
  • Sandoz
  • MORE

This is the 5th edition of 'The Corporate Reputation of Pharma - from the Perspective of Mental-Health Patient Groups'. These 2019 results are drawn from a survey of mental-health patient groups, conducted in November 2019 - February 2020.

About the 2019 survey of mental-health patient groups

  • 2019’s 75 respondent mental-health patient groups came from 30  different countries, with the highest representation being from the United States (at 10 mental-health patient groups).
  • The 75  respondent mental-health patient groups had the following geographic remits: 7% an international remit; 59% a national remit; 20% a regional (within one country); and 15% local.

On the relationships that mental-health patient groups had with pharma, 2019

  • 51% of the 75 mental-health patient groups responding to the 2019 survey worked with at least one pharma company.

What this report contains

Industry-wide analyses: The 2019 mental-health 'Corporate-Reputation' report examines the issues of importance to mental-health patient groups, including:

  • the quality of patient-group relationships with pharma;
  • levels of industry innovation; and
  • the provision of high-quality products.

Analyses are reinforced by extensive comments from 2019’s respondent mental-health patient groups, organised according to the country headquarters of the respondent patient groups.

Individual company analyses: The 6 pharma companies are reviewed by 2019’s 75 respondent mental-health patient groups for overall corporate reputation, and for performance at 12 individual indicators of corporate reputation.

Key industry-wide findings for mental-health patient organisations, 2019

Mental-health patient groups have become increasingly dissatisfied with the pharmaceutical industry. In 2019, as few as 26% of 2019’s 75 respondent mental-health patient groups judged the industry to have an “Excellent” or “Good” corporate reputation that year, ranking the industry 5th out of 9 healthcare sectors. The equivalent 2019 figure from the 1,850 respondent patient groups of all therapy areas was 46%, ranking pharma 1st out of the nine healthcare sectors. Mental-health patient groups have traditionally been more skeptical of pharma than their peers of other therapy areas. However, since 2015 (when the analyst began analysing the views of mental-health patient groups), the differences in perspective between mental-health patient groups and patient groups of other therapy areas seem to have widened.

Several reasons may explain the more negative views of mental-health patient groups. First and foremost is the fact that the number of companies engaged in researching treatments for mental-health conditions has diminished. In 2015, as many as 20 companies were included in the mental-health analyses; by 2019, the number had dropped to just six companies. The data collated by the analyst, 2015-2019, appear to reflect a growing concern by respondent mental-health patient groups at pharma’s disinvestment in mental-health R&D. In 2019, just 34% of the respondent mental-health patient groups judged the pharma industry “Excellent” or “Good” at providing high-quality products of benefit to patients - significantly down from 2015’s equivalent figure of 73%. Similarly, 26% of 2019’s respondent mental-health patient groups regarded pharma as “Excellent” or “Good” at innovation, compared with 67% in 2015.

Mental-health patient groups responding to the 2019 ‘Corporate-Reputation’ survey marked the pharma industry down on its performance at activities of importance to patients, when compared with their peers from other therapy areas. The biggest difference seen was with the quality of the relationships between these patient organisations and the pharmaceutical industry. Just 16% of the respondent mental-health patient groups called the pharma industry “Excellent” or “Good” at patient-group relationships, compared with 42% of respondent patient groups from all therapy areas―a difference of 26%.

The key issues raised by 2019’s respondent mental-health patient groups in their written feedback:

  • A lack of satisfaction with current treatments.
  • The need for better recognition of treatment side effects - and, ideally, treatments with fewer adverse reactions.
  • A lack of understanding at R&D level of the treatment needs of patients with a mental-health condition.

Key company findings, mental health, 2019

6 companies are included in the mental-health analysis of 2019’s ‘Corporate-Reputation’ results. The companies are ranked for their performance at 12 individual indicators of corporate reputation, as judged by respondent mental-health patient groups familiar with the companies.

Despite the negative sentiments expressed by many of 2019's respondent mental-health patient groups, exceptions were made for some of the pharmaceutical companies remaining in the field of mental health.
Janssen was ranked overall 1st out of 6 companies for corporate reputation in 2019 by the 52 respondent mental-health patient groups familiar with it. Janssen was ranked 1st for 9 of the 12 individual indicators of corporate reputation. Janssen was also ranked overall 1st for corporate reputation in 2019 out of 3 companies, as judged by its 31 respondent partner mental-health patient groups.

Otsuka was ranked overall 2nd out of 6 companies for corporate reputation in 2019 by the 22 respondent mental-health patient groups familiar with it. Otsuka was ranked overall joint 2nd for corporate reputation in 2019 out of 3 companies, as judged by its 17 respondent partner mental-health patient groups.

Lundbeck was ranked overall 3rd out of 6 companies for corporate reputation in 2019 by the 35 respondent mental-health patient groups familiar with it. Lundbeck was ranked overall joint 2nd for corporate reputation in 2019 out of 3 companies, as judged by its 21 respondent partner mental-health patient groups.

A note about COVID-19 and the 2019 study’s results
Covid-19 should have a relatively limited impact on many of the results of the 2019 ‘Corporate-Reputation’ study, because the survey took place (November 2019 to late-February 2020) largely before the crisis became global. However, early announcements about Covid-19 by some pharma companies (during January and February 2020) may have influenced the views of mental-health patient groups responding to the ‘Corporate-Reputation’ survey during those last two months of the survey.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eli Lilly
  • Janssen
  • Lundbeck
  • Otsuka
  • Pfizer
  • Sandoz
  • MORE

1 Executive summary
8 Relationships that mental-health patient groups have with pharma, 2019
11 Industry-wide findings, 2019
16 Rankings of 6 pharma companies, 2019 (v. 2018)among mental-health patient groups familiar with the companies
24 Rankings of 3 pharma companies, 2019 (v. 2018) among mental-health patient groups that work with the companies
32 Profiles of the 6 companies, 2019 (v. 2018)

APPENDICES
I What mental-health patient groups say on pharma(and how the industry can improve), 2019/2020
II Profiles of respondent mental-health patient groups, 2019

Tables and Charts
2 The therapy areas of 2019’s 75 respondent mental-health patient groups (Percentage of respondent mental health patient groups)
3 The percentage of respondent patient groups stating that the pharmaceutical industry had an “Excellent” or “Good” corporate reputation, 2015-2019 - mental-health patient groups versus patient groups from all therapy areas
4 The percentage of respondent mental-health patient groups stating that the pharma industry was “Excellent” or “Good” at making high-quality products, and at being innovative, 2014-2019
4 How the pharma industry performed at various activities of importance to patients: the views of mental-health patient groups, compared with patient groups from all therapy areas, 2019
7 The percentage of respondent mental-health patient groups stating “None” or “Do not know” any company that was “Best” at an activity, 2019
9 The respondent mental-health patient groups: familiarity, and partnerships, with pharma companies, 2019
10 The types of working relationships that respondent mental-health patient groups had with pharma companies, 2019
12 The corporate reputation of the pharmaceutical industry, 2019 v. 2018 - compared with that of 8 other healthcare sectors (according to respondent mental-health patient groups)
12 The corporate reputation of the pharmaceutical industry, 2015-2019 (according to respondent mental-health patient groups)
13 The perceived effectiveness of the pharmaceutical industry at carrying out specific activities, 2019 v. 2018(according to respondent mental-health patient groups)
14 Perceptions of the efficacy of the pharmaceutical industry at various activities of importance to patients and patient groups, 2014-2019 (according to respondent mental-health patient groups)
16 Rankings of 6 individual pharma companies, 2019 v. 2018 (according to respondent mental-health patient groups familiar with the company)
24 Rankings of 3 individual pharma companies, 2019 v. 2018 (according to respondent mental-health patient groups that work or partner with the company)

Profiles of the 6 companies, 2019 v. 2018; charts and tables

  • Number of respondent mental-health patient groups claiming familiarity with the company, 2019.
  • Number of respondent mental-health patient groups saying that they had a working relationship with the company, 2019.
  • Profile of respondent mental-health patient groups familiar with the company, 2019: country headquarters; specialties; geographic remit; and types of relationships.
  • Company scores among respondent mental-health patient groups familiar with the company, and which work with the company, for each of the 12 indicators of corporate reputation, 2019.
  • Percentage of the respondent mental-health patient groups that work with the company, but which also work with other companies, 2019.
  • Overall rankings for the company, according to respondent mental-health patient groups familiar with the company, 2019 v. 2018.
  • Overall rankings for the company, according to respondent mental-health patient groups that work with the company, 2019 v. 2018.
  • Company rankings for each of the 12 indicators, according to respondent mental-health patient groups familiar, or working, with the company, 2019 v. 2018.
  • Snapshot view: where the company sits in the corporate tiers for each of the 12 indicators (in the higher, the middle, or the lower tier), as assessed by respondent mental-health patient groups familiar with the company, 2019.
  • The company’s Patient Corporate Reputation Indexes (PCRIs), 2015-2019 - selected indicators.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Eli Lilly
  • Janssen
  • Lundbeck
  • Otsuka
  • Pfizer
  • Sandoz
Note: Product cover images may vary from those shown
Adroll
adroll